Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$1.57B-11.57%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph T. Morrissey Jr.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 10,000
- Beta
- 1.49
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.27
Financials
Revenue
$1.57B-11.6%Net Income
$164.00M-76.7%EBITDA
$443.00M-51.5%Free Cash Flow
$326.00M-47.9%EPS (diluted)
$0.60-78.4%Shares Outstanding (diluted)
272.38M+7.6%Operating Expenses
$504.00MCash & Debt
$1.46BReturn of Capital
$5.00MDividend per Share
$0.02Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.22B | $187.00M | $0.72 |
| 2024 | $6.40B | $864.00M | $3.36 |
| 2023 | $6.26B | $1.02B | $4.01 |
| 2022 | $6.17B | $917.00M | $3.61 |
| 2021 | $6.30B | $1.35B | $5.33 |
| 2020 | $6.53B | $2.16B | $8.52 |
| 2019 | $7.78B | $3.22B | $12.71 |
| 2018 | $9.78B | $2.15B | $8.51 |
| 2017 | $10.50B | $1.80B | $7.11 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from OGN's reported EPS growth of -24.9% a year over 8 years. Historical EPS growth of -25% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.32
- Implied price
- $3.20
- Return from $13.89
- -25.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.59 — -88.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 6 | 8 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| -25.0% | -40.6% | -37.1% | -34.2% | -31.8% | -29.6% |
| -20.0% | -36.7% | -32.9% | -29.8% | -27.2% | -25.0% |
| -15.0% | -32.7% | -28.7% | -25.5% | -22.7% | -20.3% |
| -10.0% | -28.7% | -24.5% | -21.1% | -18.1% | -15.6% |
| -5.0% | -24.8% | -20.3% | -16.7% | -13.6% | -10.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (14)
- Newszacks.com·12d ago·Neutral
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newszacks.com·23d ago·Positive
Organon (OGN) Q3 Earnings and Revenues Top Estimates Organon (OGN) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.01 per share a year ago.
View source ↗ - Newsbusinesswire.com·23d ago·Neutral
Organon Announces Quarterly Dividend JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Announces Quarterly Dividend.
View source ↗ - Newszacks.com·27d ago·Neutral
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsbusinesswire.com·34d ago·Negative
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their re…
View source ↗ - Newsbusinesswire.com·37d ago·Neutral
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.
View source ↗ - Newszacks.com·39d ago·Neutral
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newsaccessnewswire.com·40d ago·Negative
Orogen Royalties Enters into Agreement to Sell the Slaughterhouse Copper-Gold Project to Seabridge Gold VANCOUVER, BC / ACCESS Newswire / October 13, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement (the "Agreement") with a subsidiary of Seabridge Gold Inc. ("Seabridge") whereby Seabridge will acquire a 100% interest in Orogen's Slaughterhouse Iron-Oxide-Copper-Gold ("IOCG") project in Wyoming…
View source ↗ - Newsaccessnewswire.com·45d ago·Neutral
Orogen Royalties Creates a Royalty on the Cibola Copper-Gold Project in British Columbia VANCOUVER, BC / ACCESS Newswire / October 8, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement (the "Agreement") with Northern Discovery Metals (CSE:NOR) ("Northern") whereby Northern will acquire a 100% interest in the Cibola copper-gold porphyry project in British Columbia, Canada. Under the terms of the …
View source ↗ - Newszacks.com·51d ago·Neutral
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newszacks.com·62d ago·Positive
Is Trending Stock Organon & Co. (OGN) a Buy Now? Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsaccessnewswire.com·73d ago·Negative
Orogen Royalties Acquires the Serpent Gold Project in Nevada VANCOUVER, BC / ACCESS Newswire / September 10, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the acquisition of the Serpent gold project in Nevada, USA. Project Highlights Serpent is a district scale, low-sulphidation epithermal gold target located in central Nevada Focused on a series of gold-bearing structures within an eight-kilometre trend of alteration Highly anomalous gol…
View source ↗ - Newszacks.com·75d ago·Neutral
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newsbusinesswire.com·103d ago·Neutral
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability JERSEY CITY, N.J.--(BUSINESS WIRE)--HCPs, healthcare settings and pharmacies can begin REMS certification for Organon's hormone-free copper IUD, MIUDELLA, ahead of upcoming launch.
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $0.92 per share
Typical surprise +6.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Oct 30$0.94 vs $0.88beat
- Fri, Jul 31$0.85 vs $0.85beat
- Thu, Apr 30$0.71 vs $0.83miss
- Thu, Feb 12$0.63 vs $0.73miss
- Mon, Nov 10$1.01 vs $0.93beat
- Tue, Aug 5$1.00 vs $0.94beat
Estimates and results for OGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OGN officers and directors.
- Bought
- $353k
- Sold
- $553k
1 trade
2 trades
- Drinane Juliana Papasold
- Holzbaur Lynettesold
- Holzbaur Lynettebought
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Aug 13, 2026 (8d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Aug 11, 2026 (6d later)Sell$1,001 - $15,000
- Gary C. Peterssenate · MI · disclosed Nov 24, 2025 (137d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 7, 2023 (10d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 8, 2023 (13d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (29d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (29d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (21d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (28d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (22d later)Sell$100,001 - $250,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (28d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (30d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (30d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (21d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (34d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
